logo

For the Inventor, By the Inventor

Doylestown, PA, United States of America

Novira Therapeutics, Inc.

USPTO Granted Patents = 44

% Expired Patents = 93.2



Forward Citations = 439

Loading Chart...
Loading Chart...

13 inventors (with patents filed for the assignee):

goldMedal George D Hartman (38 out of 185 patents)

silverMedal Scott D Kuduk (20 out of 118 patents)

bronzeMedal Osvaldo A Flores (8 out of 13 patents)

4.  Nicholas Simon Stock (6 out of 37 patents)

5.  Ryan Christopher Clark (6 out of 18 patents)

6.  Jason Duarte Jacintho (6 out of 12 patents)

7.  Bijan Pedram (3 out of 18 patents)

8.  Austin Chen (3 out of 10 patents)

9.  Yen Truong (3 out of 17 patents)

10.  Yalda Mostofi Bravo (3 out of 20 patents)

11.  Man Iu Lam (2 out of 2 patents)

12.  Jan Martin Berke (2 out of 5 patents)

13.  Klaus G Klumpp (2 out of 12 patents)

14.  Christine Lisa Espiritu (0 patent)

15.  Jason Jacintho (0 patent)


Core Competencies:
Capsid Assembly Inhibitor
Oxadiazepinone Derivatives
Hepatitis B Antiviral Agents
Combination Therapy
Pyridyl Reverse Sulfonamides
Sulfide Alkyl Compounds
Azocane Derivatives
Azepane Derivatives
Diazepinone Derivatives
Crystalline Forms
HBV Treatment

44 patents:

1. 11129834 - Combinations and methods comprising a capsid assembly inhibitor (2021-09-28),
2. 10987359 - Oxadiazepinone derivatives and methods of treating hepatitis B infections (2021-04-27),
3. 10975077 - Diazepinone derivatives and their use in the treatment of hepatitis B infections (2021-04-13),
4. 10710959 - Sulfide alkyl compounds for HBV treatment (2020-07-14),
5. 10632112 - Combination therapy for treatment of HBV infections (2020-04-28),
6. 10556904 - Derivatives and methods of treating hepatitis B infections (2020-02-11),
7. 10544141 - Derivatives and methods of treating hepatitis B infections (2020-01-28),
8. 10538519 - Derivatives and methods of treating hepatitis B infections (2020-01-21),
9. 10537580 - Azocane and azonane derivatives and methods of treating hepatitis B infections (2020-01-21),
10. 10441589 - Combinations and methods comprising a capsid assembly inhibitor (2019-10-15),
11. 10428041 - Pyridyl reverse sulfonamides for HBV treatment (2019-10-01),
12. 10392349 - Azepane derivatives and methods of treating hepatitis B infections (2019-08-27),
13. 10364228 - Azepane derivatives and methods of treating hepatitis B infections (2019-07-30),
14. 10213420 - Combination therapy for treatment of HBV infections (2019-02-26),
15. 10196376 - Hepatitis B antiviral agents (2019-02-05),
Company Overview
Novira Therapeutics, Inc., based in Doylestown, PA, specializes in the development of innovative antiviral therapies, particularly targeting Hepatitis B. The company focuses on advancing its proprietary capsid assembly inhibitors and exploring various chemical compounds, including oxadiazepinone derivatives and sulfide alkyl compounds. Through combination therapy approaches and the use of pyridyl reverse sulfonamides and azepane derivatives, Novira aims to provide effective treatment options for chronic viral infections, contributing to the broader field of antiviral research.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Novira Therapeutics, Inc. USPTO Patent Assignee Logo
44 Patents

#1 in Doylestown, PA

#296 in Pennsylvania

#7,960 in US

#15,768 in the World

Doylestown, PA (US)
Doylestown, PA, United States of America

Novira Therapeutics, Inc.

Forward Citations = 439

13 inventors:

goldMedal George D Hartman (38 out of 185 patents)

silverMedal Scott D Kuduk (20 out of 118 patents)

bronzeMedal Osvaldo A Flores (8 out of 13 patents)

4.  Nicholas Simon Stock (6 out of 37 patents)

5.  Ryan Christopher Clark (6 out of 18 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Novira Therapeutics, Inc.. Retrieved from https://idiyas.com/company/novira-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…